News

Utidelone Injection, developed by Beijing Biostar Pharmaceuticals, is a new natural microbial small-molecule anticancer drug that is a genetically engineered epothilone derivative. It is a new non- taxane

DZD4205 (Golidocitinib) is a selective JAK1 inhibitor in relapsed/refractory peripheral T-Cell lymphoma. The orally available, JAK1-specific inhibitor has showed that 21 (42.9%) out of the 49 patients have

Led by Perceptive Advisors, the financing round has seen participation from existing investors RA Capital Management, Wellington Management, and Moore Strategic Ventures. The new investors include Declaration Partners,

SBT101 is in development for compensating the disease-causing ABCD1 mutation. It is designed for reducing very long chain fatty acid (VLCFA) levels and increase ABCD1 expression for AMN

These patients have received at least one prior systemic therapy earlier. Adagrasib is an investigational, potent oral small-molecule therapy which is designed to shrink difficult-to-treat cancers that are

As per the terms of the collaboration, Adcentrx will specify the targets against which AvantGen will screen for new antibodies by making use of its yeast display system.

The acceptance by the FDA is based on the positive data from a Phase II study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

As part of the collaboration, the companies will use Nurosene’s core AI tools, NetraHealthAtlas, to speed up the drug discovery process. NetraHealthAtlas is designed to produce insights regarding

Lead founding investors Polaris Partners and Timothy A. Springer participated in the funding round, in addition to new investors Samsara BioCapital, Boxer Capital, GV, and management and founders.